Contraindications to receiving PENBRAYA meningococcal vaccine include a history of severe allergic reaction to any of the ingredients found within the vaccine.
The PENBRAYA vaccine package insert also warns that persons with a previous medical history of Guillain-Barre Syndrome (GBS) may be at an increased risk of the disease following administration with the vaccine. The decision to vaccinate should be made only after careful consideration of the potential risks and possible benefits to vaccination.
There are no well-controlled or adequate studies on the use of PENBRAYA vaccine in pregnant women and no available data on the impact of PENBRAYA vaccine on breastfeeding infants or on human milk excretion and production.
PENBRAYA vaccine is FDA approved for use in individuals 10 through 25 years of age. PENBRAYA vaccine is not approved for use in children younger than 10 years of age or adults older than 25 years.
NVIC “Quick Facts” is not a substitute for becoming fully informed about Meningococcal disease, meningitis and the Meningococcal vaccine. NVIC recommends consumers read the more complete information following the "Quick Facts", as well as the vaccine manufacturer product information inserts, and speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child.
